204 related articles for article (PubMed ID: 30639166)
1. A novel monoallelic gain of function mutation in p110δ causing atypical activated phosphoinositide 3-kinase δ syndrome (APDS-1).
Lougaris V; Baronio M; Moratto D; Tampella G; Gazzurelli L; Facchetti M; Martire B; Cardinale F; Lanzarotto F; Bondioni MP; Villanacci V; Grimbacher B; Plebani A
Clin Immunol; 2019 Mar; 200():31-34. PubMed ID: 30639166
[TBL] [Abstract][Full Text] [Related]
2. Activated phosphoinositide 3-dinase delta syndrome (APDS): An update.
Lougaris V; Cancrini C; Rivalta B; Castagnoli R; Giardino G; Volpi S; Leonardi L; La Torre F; Federici S; Corrente S; Cinicola BL; Soresina A; Marseglia GL; Cardinale F
Pediatr Allergy Immunol; 2022 Jan; 33 Suppl 27(Suppl 27):69-72. PubMed ID: 35080319
[TBL] [Abstract][Full Text] [Related]
3. Genetic Defects in Phosphoinositide 3-Kinase δ Influence CD8
Cannons JL; Preite S; Kapnick SM; Uzel G; Schwartzberg PL
Front Immunol; 2018; 9():1758. PubMed ID: 30116245
[TBL] [Abstract][Full Text] [Related]
4. Paediatric MAS/HLH caused by a novel monoallelic activating mutation in p110δ.
Lougaris V; Baronio M; Castagna A; Tessarin G; Rossi S; Gazzurelli L; Benvenuto A; Moratto D; Chiarini M; Cattalini M; Facchetti M; Palumbo L; Giliani S; Girelli MF; Badolato R; Bondioni MP; Facchetti F; Meini A; Plebani A
Clin Immunol; 2020 Oct; 219():108543. PubMed ID: 32681977
[TBL] [Abstract][Full Text] [Related]
5. Respiratory Manifestations of the Activated Phosphoinositide 3-Kinase Delta Syndrome.
Condliffe AM; Chandra A
Front Immunol; 2018; 9():338. PubMed ID: 29556229
[TBL] [Abstract][Full Text] [Related]
6. Clinical, Immunological, and Genetic Features in Patients with Activated PI3Kδ Syndrome (APDS): a Systematic Review.
Jamee M; Moniri S; Zaki-Dizaji M; Olbrich P; Yazdani R; Jadidi-Niaragh F; Aghamahdi F; Abolhassani H; Condliffe AM; Aghamohammadi A; Azizi G
Clin Rev Allergy Immunol; 2020 Dec; 59(3):323-333. PubMed ID: 31111319
[TBL] [Abstract][Full Text] [Related]
7. Dysregulated actin dynamics in activated PI3Kδ syndrome.
Wallace JG; Zambrano-Rodas P; Córdova-Calderón W; Estrada-Turriate S; Mendoza-Quispe D; Limache Ontiveros Y; Geha RS; Chou J; Platt CD
Clin Immunol; 2020 Jan; 210():108311. PubMed ID: 31760094
[TBL] [Abstract][Full Text] [Related]
8. Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: A large patient cohort study.
Coulter TI; Chandra A; Bacon CM; Babar J; Curtis J; Screaton N; Goodlad JR; Farmer G; Steele CL; Leahy TR; Doffinger R; Baxendale H; Bernatoniene J; Edgar JD; Longhurst HJ; Ehl S; Speckmann C; Grimbacher B; Sediva A; Milota T; Faust SN; Williams AP; Hayman G; Kucuk ZY; Hague R; French P; Brooker R; Forsyth P; Herriot R; Cancrini C; Palma P; Ariganello P; Conlon N; Feighery C; Gavin PJ; Jones A; Imai K; Ibrahim MA; Markelj G; Abinun M; Rieux-Laucat F; Latour S; Pellier I; Fischer A; Touzot F; Casanova JL; Durandy A; Burns SO; Savic S; Kumararatne DS; Moshous D; Kracker S; Vanhaesebroeck B; Okkenhaug K; Picard C; Nejentsev S; Condliffe AM; Cant AJ
J Allergy Clin Immunol; 2017 Feb; 139(2):597-606.e4. PubMed ID: 27555459
[TBL] [Abstract][Full Text] [Related]
9. Enhanced AKT Phosphorylation of Circulating B Cells in Patients With Activated PI3Kδ Syndrome.
Asano T; Okada S; Tsumura M; Yeh TW; Mitsui-Sekinaka K; Tsujita Y; Ichinose Y; Shimada A; Hashimoto K; Wada T; Imai K; Ohara O; Morio T; Nonoyama S; Kobayashi M
Front Immunol; 2018; 9():568. PubMed ID: 29675019
[TBL] [Abstract][Full Text] [Related]
10. The case of an APDS patient: Defects in maturation and function and decreased in vitro anti-mycobacterial activity in the myeloid compartment.
Chiriaco M; Brigida I; Ariganello P; Di Cesare S; Di Matteo G; Taus F; Cittaro D; Lazarevic D; Scarselli A; Santilli V; Attardi E; Stupka E; Giannelli S; Fraziano M; Finocchi A; Rossi P; Aiuti A; Palma P; Cancrini C
Clin Immunol; 2017 May; 178():20-28. PubMed ID: 26732860
[TBL] [Abstract][Full Text] [Related]
11. PIK3R1 Mutation Associated with Hyper IgM (APDS2 Syndrome): A Case Report and Review of the Literature.
Yazdani R; Hamidi Z; Babaha F; Azizi G; Fekrvand S; Abolhassani H; Aghamohammadi A
Endocr Metab Immune Disord Drug Targets; 2019; 19(7):941-958. PubMed ID: 30799802
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of B-cell intracellular signaling by monitoring the PI3K-Akt axis in patients with common variable immunodeficiency and activated phosphoinositide 3-kinase delta syndrome.
Del Pino-Molina L; Torres Canizales JM; Rodríguez-Pena R; López-Granados E
Cytometry B Clin Cytom; 2021 Jul; 100(4):460-466. PubMed ID: 32961022
[TBL] [Abstract][Full Text] [Related]
13. Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase δ syndrome 2: A cohort study.
Elkaim E; Neven B; Bruneau J; Mitsui-Sekinaka K; Stanislas A; Heurtier L; Lucas CL; Matthews H; Deau MC; Sharapova S; Curtis J; Reichenbach J; Glastre C; Parry DA; Arumugakani G; McDermott E; Kilic SS; Yamashita M; Moshous D; Lamrini H; Otremba B; Gennery A; Coulter T; Quinti I; Stephan JL; Lougaris V; Brodszki N; Barlogis V; Asano T; Galicier L; Boutboul D; Nonoyama S; Cant A; Imai K; Picard C; Nejentsev S; Molina TJ; Lenardo M; Savic S; Cavazzana M; Fischer A; Durandy A; Kracker S
J Allergy Clin Immunol; 2016 Jul; 138(1):210-218.e9. PubMed ID: 27221134
[TBL] [Abstract][Full Text] [Related]
14. Case Report: Activating
Lu M; Gu W; Sheng Y; Wang J; Xu X
Front Immunol; 2021; 12():670312. PubMed ID: 33995405
[TBL] [Abstract][Full Text] [Related]
15. Exhaustion of the CD8
Wentink MWJ; Mueller YM; Dalm VASH; Driessen GJ; van Hagen PM; van Montfrans JM; van der Burg M; Katsikis PD
Front Immunol; 2018; 9():446. PubMed ID: 29563914
[TBL] [Abstract][Full Text] [Related]
16. A Rare Case of Activated Phosphoinositide 3-Kinase Delta Syndrome (APDS) Presenting With Hemophagocytosis Complicated With Hodgkin Lymphoma.
Cansever M; Zietara N; Chiang SCC; Ozcan A; Yilmaz E; Karakukcu M; Rohlfs M; Somekh I; Canoz O; Abdulrezzak U; Bryceson Y; Klein C; Unal E; Patiroglu T
J Pediatr Hematol Oncol; 2020 Mar; 42(2):156-159. PubMed ID: 31033788
[TBL] [Abstract][Full Text] [Related]
17. Conformational disruption of PI3Kδ regulation by immunodeficiency mutations in
Dornan GL; Siempelkamp BD; Jenkins ML; Vadas O; Lucas CL; Burke JE
Proc Natl Acad Sci U S A; 2017 Feb; 114(8):1982-1987. PubMed ID: 28167755
[TBL] [Abstract][Full Text] [Related]
18. Activating PI3Kδ mutations in a cohort of 669 patients with primary immunodeficiency.
Elgizouli M; Lowe DM; Speckmann C; Schubert D; Hülsdünker J; Eskandarian Z; Dudek A; Schmitt-Graeff A; Wanders J; Jørgensen SF; Fevang B; Salzer U; Nieters A; Burns S; Grimbacher B
Clin Exp Immunol; 2016 Feb; 183(2):221-9. PubMed ID: 26437962
[TBL] [Abstract][Full Text] [Related]
19. Activated PI3 Kinase Delta Syndrome: From Genetics to Therapy.
Michalovich D; Nejentsev S
Front Immunol; 2018; 9():369. PubMed ID: 29535736
[TBL] [Abstract][Full Text] [Related]
20. Immune Dysregulation and Disease Pathogenesis due to Activating Mutations in PIK3CD-the Goldilocks' Effect.
Tangye SG; Bier J; Lau A; Nguyen T; Uzel G; Deenick EK
J Clin Immunol; 2019 Feb; 39(2):148-158. PubMed ID: 30911953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]